Share chart Turnstone Biologics Corp. Common Stock
Extended chart
Simple chart
About Turnstone Biologics Corp. Common Stock
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. more detailsMain settings
| IPO date | 2023-07-21 |
|---|---|
| ISIN | US90042W1009 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | link |
| Change price per day: | 0% (0.3321) |
|---|---|
| Change price per week: | -0.7768% (0.3347) |
| Change price per month: | -2.32% (0.34) |
| Change price per 3 month: | -11.46% (0.3751) |
| Change price per half year: | -34.24% (0.505) |
| Change price per year: | -87.37% (2.63) |
| Change price per year to date: | -26.8% (0.4537) |
Grade
Underestimation
| Title | Value | Grade |
|---|---|---|
| P/S | 1.78 | 8 |
| P/BV | 0.3638 | 10 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
|---|---|---|
| ROA, % | -92.63 | 0 |
| ROE, % | -108.87 | 0 |
| ROIC, % | 0 | 0 |
Dividends
| Title | Value | Grade |
|---|---|---|
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
|---|---|---|
| Debt/EBITDA | -0.0164 | 10 |
| Debt/Ratio | 0.0296 | 10 |
| Debt/Equity | 0.2756 | 10 |
Growth impulse
| Title | Value | Grade |
|---|---|---|
| Yield Revenue, % | -80.94 | 0 |
| Yield Ebitda, % | -310.74 | 0 |
| Yield EPS, % | -304.99 | 0 |
Main owners
| Institutions | Volume | Share, % |
|---|---|---|
| Orbimed Advisors LLC. | 3 099 265 | 13.42 |
| FMR, LLC | 2 546 661 | 11.02 |
| Bank of America Corporation | 914 058 | 3.96 |
| Point72 Asset Management, L.P. | 833 333 | 3.61 |
| Eventide Asset Management LLC | 708 317 | 3.07 |
| Citadel Advisors Llc | 688 468 | 2.98 |
| PFM Health Sciences, LP | 633 313 | 2.74 |
| 72 Investment Holdings, LLC | 549 981 | 2.38 |
| Sectoral Asset Management, Inc. | 517 648 | 2.24 |
| Blackrock Inc. | 301 925 | 1.31 |
Company management
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Sammy J. Farah M.B.A., Ph.D. | President, CEO & Director | 678.51k | 1973 (52 years) |
| Dr. Venkat Ramanan Ph.D. | Chief Financial Officer | 346.13k | 1970 (55 years) |
| Dr. Michael F. Burgess M.D., MBChB, Ph.D. | Interim Chief Medical Officer & Executive Director | 212.69k | 1963 (62 years) |
| Ms. Saryah Azmat | Chief Business Officer | 479.73k | 1990 (35 years) |
| Dr. Vijay Chiruvolu M.B.A., Ph.D. | Interim Chief Technology Officer | N/A | 1962 (63 years) |
| Dr. David Stojdl Ph.D. | Senior Vice President of Research & Discovery | ||
| Dr. Ines Verdon M.D. | Senior Vice President of Clinical Development |
About company
Address: United States, LA Jolla. CA, 9310 Athena Circle - Open in google maps, Open in yandex maps
Website: https://turnstonebio.com
Website: https://turnstonebio.com
